NasdaqGM:ADMABiotechs
Assessing ADMA Biologics (ADMA) Valuation After Fresh Analyst Upgrades And Strong Buy Sentiment
Analyst sentiment around ADMA Biologics (ADMA) has turned more positive, with a consensus Strong Buy rating and upward revisions to earnings estimates. This has drawn fresh attention to the stock and its recent share price performance.
See our latest analysis for ADMA Biologics.
Despite the recent analyst optimism, ADMA Biologics' 1 day share price return of a 4.66% decline and 7 day share price return of a 9.6% decline add to a year to date share price return of a 19.91% decline. However,...